AB680

Phase 1Small molecule

Arcus Biosciences

AB680 is one of 42 small molecule programs targeting Metastatic Colorectal Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Colorectal CancerActive, not recruiting

Advanced Pancreatic CancerActive, not recruiting

Metastatic Colorectal CancerPhase 1/Phase 2

Active, not recruiting

Advanced Pancreatic CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

698 competitors in Metastatic Colorectal Cancer

#DrugCompanyPhaseTrials

Vectibix

Amgen

Phase 3

45 2

Erbitux

IImclone

Phase 3

113 3

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

94 4

Braftovi

Pfizer

Phase 3

11 5

Sutent

Pfizer

Phase 3

3 6

Lynparza

AstraZeneca

Phase 3

2 7

Lumakras

Amgen

Phase 3

2 8

Celebrex

PPhiladelphia Eye Associates

Phase 3

9 9

Azulfidine

Pfizer

Phase 3

1 10

Lenvima

Eisai

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Active, not recruiting

Advanced Pancreatic Cancer

NCT04104672

Clinical

Trials by Indication[1]

Oral1 trial

A Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy Volunteers

Completed· Arcus Biosciences logo

Arcus Biosciences·Phase 1·NCT04575311·32 enrolled

Metastatic Colorectal Cancer1 trial

An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.

Completed· Arcus Biosciences logo

Arcus Biosciences·Phase 1/2·NCT04660812·227 enrolled

Advanced Pancreatic Cancer1 trial

A Phase 1 Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants With Gastrointestinal Malignancies

Active, not recruiting· Arcus Biosciences logo

Arcus Biosciences·Phase 1·NCT04104672·196 enrolled

Unspecified1 trial

A Study to Investigate the Safety of AB680 in Healthy Volunteers

Completed· Arcus Biosciences logo

Arcus Biosciences·Phase 1·NCT03677973·64 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for AB680. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AB680 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AB680. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Arcus Biosciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Arcus Biosciences

AB680

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Oral1 trial

Metastatic Colorectal Cancer1 trial

Advanced Pancreatic Cancer1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News